Oncopeptides Logo

Oncopeptides

Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.

ONCO | ST

Overview

Corporate Details

ISIN(s):
SE0009414576 (+4 more)
LEI:
549300J9WWQ5CBYQ1M77
Country:
Sweden
Address:
Luntmakargatan 46, 111 37 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oncopeptides AB is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers, particularly hematological diseases. Founded in 2000, the company leverages its proprietary Peptide Drug Conjugate technology platforms to develop innovative treatments. Its lead product, Pepaxti® (melflufen), is a treatment for adult patients with relapsed refractory multiple myeloma (RRMM). Oncopeptides is actively commercializing Pepaxti in Europe and conducts real-world evidence studies to support the drug's effectiveness and tolerability in clinical practice. The company's mission is to address significant unmet medical needs and provide hope to cancer patients through scientific innovation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 08:30
Regulatory News Service
Oncopeptides har utsett valberedningen
Swedish 63.1 KB
2025-11-21 08:30
Regulatory News Service
Oncopeptides announces the Nomination Committee
English 62.7 KB
2025-11-05 08:00
Quarterly Report
Swedish 550.9 KB
2025-11-05 08:00
Quarterly Report
English 636.0 KB
2025-10-31 08:30
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-10-31 08:30
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Oncopeptides
English 67.6 KB
2025-10-28 09:37
Major Shareholding Notification
Swedish 10.4 KB
2025-10-13 18:45
Capital/Financing Update
Oncopeptides issues warrants to fulfil its obligations under loan agreement wit…
English 76.0 KB
2025-10-13 18:45
Capital/Financing Update
Oncopeptides emitterar teckningsoptioner för att uppfylla sina skyldigheter und…
Swedish 76.7 KB
2025-10-10 13:36
Major Shareholding Notification
Swedish 10.8 KB
2025-10-08 09:50
Major Shareholding Notification
Swedish 10.5 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Antal aktier och röster i Oncopeptides
Swedish 68.1 KB
2025-09-30 10:00
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in Oncopeptides
English 67.7 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides’ rights issue oversubscribed to approximately 157 percent
English 86.0 KB
2025-09-17 08:30
Share Issue/Capital Change
Oncopeptides företrädesemission övertecknad till cirka 157 procent
Swedish 86.2 KB

Automate Your Workflow. Get a real-time feed of all Oncopeptides filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oncopeptides

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oncopeptides via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-15 David Augustsson Other Buy 1,250 6,350.00 SEK
2024-04-15 David Augustsson Other Buy 1,250 6,312.50 SEK
2024-04-15 David Augustsson Other Buy 438 2,225.04 SEK
2024-04-15 David Augustsson Other Buy 60 303.60 SEK
2024-04-15 David Augustsson Other Buy 2 10.02 SEK
2023-09-08 David Augustsson Other Buy 2,296 17,706.75 SEK
2023-08-10 David Augustsson Other Buy 1,704 14,995.20 SEK
2023-05-04 Nicolaas Bakker Other Buy 5,000 42,380.00 SEK
2022-10-10 Nicolaas Bakker Other Buy 15,000 164,400.00 SEK
2022-08-30 Per Wold-Olsen Other Buy 2,050 55,350.00 SEK

Peer Companies

Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea
311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea
063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.
United States of America
CLSD
Clene Inc. Logo
Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.
United States of America
CLNN
Climb Bio, Inc. Logo
Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.
United States of America
CLYM
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea
058820
Cocrystal Pharma, Inc. Logo
Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.
United States of America
COCP
Co-Diagnostics, Inc. Logo
Develops patented PCR solutions for accurate infectious disease diagnostics.
United States of America
CODX

Talk to a Data Expert

Have a question? We'll get back to you promptly.